RIGL · Company research
Rigel Pharmaceuticals Inc. (New) (RIGL): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
20records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| A cancer drug produced responses in 53% of patients with several types of cancer - Stock Titan | A cancer drug produced responses in 53% of patients with several types of cancer Stock Titan | View source ↗ | Stock Titan | Oct 19, 2026 | neutral | 0 | 0.6 |
| Rigel Pharmaceuticals (RIGL) Institutional Ownership 2026 $RIGL - MarketBeat | Rigel Pharmaceuticals (RIGL) Institutional Ownership 2026 $RIGL MarketBeat | View source ↗ | MarketBeat | Oct 15, 2026 | neutral | 0 | 0.6 |
| Rigel Pharmaceuticals, Inc. (RIGL) stock price, news, quote and history - Yahoo Finance UK | Rigel Pharmaceuticals, Inc. (RIGL) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 14, 2026 | neutral | 0 | 0.6 |
| Rigel Pharmaceuticals, Inc. (RIGL) Stock Price, News, Quote & History - Yahoo! Finance Canada | Rigel Pharmaceuticals, Inc. (RIGL) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 13, 2026 | neutral | 0 | 0.6 |
| Rigel Pharmaceuticals, Inc. (RIGL) stock price, news, quote and history - Yahoo Finance Australia | Rigel Pharmaceuticals, Inc. (RIGL) stock price, news, quote and history Yahoo Finance Australia | View source ↗ | Yahoo Finance Australia | Oct 13, 2026 | neutral | 0 | 0.6 |
| Reasons Why Investors Should Consider Betting on Arvinas Stock | Arvinas received FDA approval for Veppanu (vepdegestrant) in May 2026, marking the first FDA-approved PROTAC protein degrader for treating ESR1-mutated breast cancer. The company out-licensed global rights to Rigel Pharmaceuticals for $70 million upfront plus up to $320 million in milestones and royalties. Arvinas' diversified pipeline includes candidates for lymphoma, Parkinson's disease, and solid tumors with data expected through 2027. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.667 | 1 |
| Reasons Why Investors Should Consider Betting on Arvinas Stock | Arvinas received FDA approval for Veppanu (vepdegestrant) in May 2026, marking the first FDA-approved PROTAC protein degrader for treating ESR1-mutated breast cancer. The company out-licensed global rights to Rigel Pharmaceuticals for $70 million upfront plus up to $320 million in milestones and royalties. Arvinas' diversified pipeline includes candidates for lymphoma, Parkinson's disease, and solid tumors with data expected through 2027. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.667 | 1 |
| Rigel Pharmaceuticals (RIGL) Short Interest & Short Float | Updated Oct 2026 $RIGL - MarketBeat | Rigel Pharmaceuticals (RIGL) Short Interest & Short Float | Updated Oct 2026 $RIGL MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| 18 new employees at Rigel receive stock awards vesting over four years. - Stock Titan | 18 new employees at Rigel receive stock awards vesting over four years. Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| Rigel (RIGL) Drops -1.36% — Key Support at $46.26 2026-09-29 - New Listing Stocks - dars.gov.et | Rigel (RIGL) Drops -1.36% — Key Support at $46.26 2026-09-29 - New Listing Stocks dars.gov.et | View source ↗ | dars.gov.et | Sep 29, 2026 | neutral | 0 | 0.6 |
| Rigel Pharmaceuticals (RIGL) Stock Sees Fair Value Lift As Veppanu Launch Adds Growth Hope - Yahoo Finance | Rigel Pharmaceuticals (RIGL) Stock Sees Fair Value Lift As Veppanu Launch Adds Growth Hope Yahoo Finance | View source ↗ | Yahoo Finance | Aug 15, 2026 | neutral | 0 | 0.6 |
| Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead (NASDAQ:RIGL) - Seeking Alpha | Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead (NASDAQ:RIGL) Seeking Alpha | View source ↗ | Seeking Alpha | Aug 5, 2026 | neutral | 0 | 0.6 |
| Rigel Pharmaceuticals (RIGL) Dips 3.8% as Shares Test Key Support Levels - High Beta Stocks - https://www.dars.gov.et/ | Rigel Pharmaceuticals (RIGL) Dips 3.8% as Shares Test Key Support Levels - High Beta Stocks https://www.dars.gov.et/ | View source ↗ | https://www.dars.gov.et/ | Jul 30, 2026 | neutral | 0 | 0.6 |
| Rigel board member Alison Hannah steps in as chief medical officer - Stock Titan | Rigel board member Alison Hannah steps in as chief medical officer Stock Titan | View source ↗ | Stock Titan | Jul 1, 2026 | neutral | 0 | 0.6 |
| RIGL Forecast — Price Target — Prediction for 2027 - TradingView | RIGL Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 27, 2026 | neutral | 0 | 0.6 |
| A Look At The Transformation Around Rigel Pharmaceuticals (NASDAQ:RIGL) - Seeking Alpha | A Look At The Transformation Around Rigel Pharmaceuticals (NASDAQ:RIGL) Seeking Alpha | View source ↗ | Seeking Alpha | Jun 20, 2026 | neutral | 0 | 0.6 |
| RIGL Stock Jumps 15%, Short Interest Surges To Record High – Why Is Retail Eyeing A Further 40% Upside? - Stocktwits | RIGL Stock Jumps 15%, Short Interest Surges To Record High – Why Is Retail Eyeing A Further 40% Upside? Stocktwits | View source ↗ | Stocktwits | May 12, 2026 | neutral | 0 | 0.6 |
| Rigel Pharmaceuticals Was Easy To Dismiss - Now It's Hard To Ignore (NASDAQ:RIGL) - Seeking Alpha | Rigel Pharmaceuticals Was Easy To Dismiss - Now It's Hard To Ignore (NASDAQ:RIGL) Seeking Alpha | View source ↗ | Seeking Alpha | Apr 9, 2026 | neutral | 0 | 0.6 |
| Rigel Pharmaceuticals, Inc. Common Stock (RIGL) Stock - Gotrade | Rigel Pharmaceuticals, Inc. Common Stock (RIGL) Stock Gotrade | View source ↗ | Gotrade | Jan 13, 2026 | neutral | 0 | 0.6 |
| Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Too Much Debt? - Simply Wall Street | Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Too Much Debt? Simply Wall Street | View source ↗ | Simply Wall Street | Jan 8, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.